Levobetaxolol
This article does not cite any sources. (December 2009) (Learn how and when to remove this template message) |
![]() |
|
![]() |
|
Clinical data | |
---|---|
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
Pregnancy category |
|
Routes of administration |
topical (ophthalmic) |
ATC code | none |
Pharmacokinetic data | |
Biological half-life | 20 hours |
Identifiers | |
|
|
CAS Number | 93221-48-8 ![]() |
PubChem (CID) | 60657 |
IUPHAR/BPS | 8035 |
ChemSpider | 54669 ![]() |
UNII | 75O9XHA4TU ![]() |
ChEBI | CHEBI:59254 ![]() |
ChEMBL | CHEMBL1201274 ![]() |
Chemical and physical data | |
Formula | C18H29NO3 |
Molar mass | 307.427 g/mol |
3D model (Jmol) | Interactive image |
|
|
|
|
![]() ![]() |
Levobetaxolol is a drug used to lower the pressure in the eye in treating conditions such as glaucoma. It is typically marketed as a 0.5% ophthalmic solution of levobetaxolol hydrochloride under the trade name Betaxon. Levobetaxolol is a beta-adrenergic receptor inhibitor (beta blocker).
Effect[edit]
Levobetaxolol inhibits the beta-1-adrenergic receptor. When applied topically, it reduces intra-ocular pressure (IOP) by 16-23% depending on time of day and the individual. It is indicated for IOP reduction in patients with open-angle glaucoma or ocular hypertension. Levobetaxolol has fewer cardiovascular side effects than other beta blockers.
Contraindications and side effects[edit]
Levobetaxolol should not be used by people who have sinus bradycardia, atrioventricular block, cardiogenic shock, or overt cardiac failure.
The drug has been associated with bradycardia and hypertension.